SERES THERAPEUTICS INC. - COMMON STOCK

Seres Therapeutics Announces Receipt of Expected $50 Million Installment Payment Related to VOWST Sale

16 Jan 2025 06:00:00 By Nasdaq GlobeNewswire

Seres Therapeutics Announces New Translational Biomarker Results from SER-155 Phase 1b Clinical Study and Provides Corporate Updates

09 Jan 2025 06:00:00 By Nasdaq GlobeNewswire

Seres Therapeutics to Participate in 2025 J.P. Morgan Healthcare Conference

16 Dec 2024 06:00:00 By Nasdaq GlobeNewswire

FDA Grants Breakthrough Therapy Designation to Seres Therapeutics’ SER-155 for Reduction of Bloodstream Infections in Adults Undergoing Allogeneic Hematopoietic Stem Cell Transplant (allo-HSCT)

09 Dec 2024 06:00:00 By Nasdaq GlobeNewswire

Seres Therapeutics to Participate in Piper Sandler Healthcare Conference

22 Nov 2024 06:00:00 By Nasdaq GlobeNewswire

Seres Therapeutics Reports Third Quarter 2024 Financial Results and Provides Business Updates

13 Nov 2024 06:00:00 By Nasdaq GlobeNewswire

Seres Therapeutics to Announce Third Quarter 2024 Financial Results and Business Updates on November 13, 2024

06 Nov 2024 06:00:00 By Nasdaq GlobeNewswire

Seres Therapeutics Announces Completion of VOWST™ Asset Sale to Société des Produits Nestlé S.A

30 Sep 2024 16:15:00 By Nasdaq GlobeNewswire

Seres Therapeutics Stockholders Approve Sale of VOWST™ to Nestlé Health Science; Sale Expected to Close on September 30

26 Sep 2024 15:01:00 By Nasdaq GlobeNewswire

Seres Therapeutics to Participate in Cantor 2024 Global Healthcare Conference

13 Sep 2024 06:00:00 By Nasdaq GlobeNewswire

Seres Therapeutics Reports SER-155 Phase 1b Placebo-Controlled Cohort 2 Study Safety and Clinical Results in Patients Undergoing Allogeneic Hematopoietic Stem Cell Transplant (allo-HSCT)

12 Sep 2024 06:00:00 By Nasdaq GlobeNewswire

Seres Therapeutics Reports Second Quarter 2024 Financial Results and Provides Business Updates

13 Aug 2024 06:00:01 By Nasdaq GlobeNewswire

Seres Therapeutics Announces Signing of VOWST™ Asset Purchase Agreement with Nestlé Health Science

06 Aug 2024 06:00:00 By Nasdaq GlobeNewswire

Seres Therapeutics to Announce Second Quarter 2024 Financial Results and Business Update on August 13, 2024

06 Aug 2024 06:00:00 By Nasdaq GlobeNewswire

Seres Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

07 Jun 2024 15:00:00 By Nasdaq GlobeNewswire

Seres Therapeutics Enters Into Memorandum of Understanding For Vowst™ Asset Sale to Nestlé Health Science

06 Jun 2024 05:30:00 By Nasdaq GlobeNewswire

NetDania - New 12 months Low: SERES THERAPEUTICS INC. - COMMON STOCK

19 Apr 2024 08:45:04 By NetDania Notify

NetDania - New 12 months Low: SERES THERAPEUTICS INC. - COMMON STOCK

18 Apr 2024 12:43:28 By NetDania Notify

NetDania - New 12 months Low: SERES THERAPEUTICS INC. - COMMON STOCK

17 Apr 2024 10:09:31 By NetDania Notify

NetDania - New 12 months Low: SERES THERAPEUTICS INC. - COMMON STOCK

16 Apr 2024 08:49:29 By NetDania Notify